PRMT5 as a druggable target for glioblastoma therapy

摘要: Background In spite of standard multimodal therapy consisting surgical resection followed by radiation and concurrent chemotherapy, prognosis for glioblastoma (GBM) patients remains poor. The identification both differentiated undifferentiated "stem cell like" populations in the tumor highlights significance finding novel targets that affect heterogeneous population. Protein arginine methyltransferase 5 (PRMT5) is one such candidate gene whose nuclear expression correlates with poor survival has been reported to be required GBM cells self-renewal cells. current study we screened specificity efficacy 4 PRMT5 inhibitors treatment GBM. Methods Efficacies these were using an vitro neurosphere model vivo intracranial zebrafish glioma. Standard molecular biology methods employed investigate changes cycle, growth, senescence. Results studies revealed among inhibitors, compound (CMP5) mirrored effects knockdown wherein it led apoptosis drove primary patient derived into a nonreplicative senescent state. Conclusion antitumor combined CMP5 underscores importance developing translation.